174 related articles for article (PubMed ID: 26719671)
1. The study on the preparation and characterization of gene-loaded immunomagnetic albumin nanospheres and their anti-cell proliferative effect combined with magnetic fluid hyperthermia on GLC-82 cells.
Zhang H; Hou X; Lin M; Wang L; Li H; Yuan C; Liang C; Zhang J; Zhang D
Drug Des Devel Ther; 2015; 9():6445-60. PubMed ID: 26719671
[TBL] [Abstract][Full Text] [Related]
2. Magnetic albumin immuno-nanospheres as an efficient gene delivery system for a potential use in lung cancer: preparation, in vitro targeting and biological effect analysis.
Hou X; Zhang H; Li H; Zhang D
J Drug Target; 2016; 24(3):247-56. PubMed ID: 26325231
[TBL] [Abstract][Full Text] [Related]
3. Study of the combined treatment of lung cancer using gene-loaded immunomagnetic albumin nanospheres in vitro and in vivo.
Zhang H; Liang C; Hou X; Wang L; Zhang D
Int J Nanomedicine; 2016; 11():1039-50. PubMed ID: 27042059
[TBL] [Abstract][Full Text] [Related]
4. GEM-loaded magnetic albumin nanospheres modified with cetuximab for simultaneous targeting, magnetic resonance imaging, and double-targeted thermochemotherapy of pancreatic cancer cells.
Wang L; An Y; Yuan C; Zhang H; Liang C; Ding F; Gao Q; Zhang D
Int J Nanomedicine; 2015; 10():2507-19. PubMed ID: 25848268
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor-targeted ultra-small superparamagnetic iron oxide particles for magnetic resonance molecular imaging of lung cancer cells in vitro.
Chen CL; Hu GY; Mei Q; Qiu H; Long GX; Hu GQ
Chin Med J (Engl); 2012 Jul; 125(13):2322-8. PubMed ID: 22882856
[TBL] [Abstract][Full Text] [Related]
6. Identification of epidermal growth factor receptor-positive glioblastoma using lipid-encapsulated targeted superparamagnetic iron oxide nanoparticles in vitro.
Chen HL; Hsu FT; Kao YJ; Liu HS; Huang WZ; Lu CF; Tsai PH; Ali AAA; Lee GA; Chen RJ; Chen CY
J Nanobiotechnology; 2017 Nov; 15(1):86. PubMed ID: 29166921
[TBL] [Abstract][Full Text] [Related]
7. Enhanced cytotoxic activity of cetuximab in EGFR-positive lung cancer by conjugating with gold nanoparticles.
Qian Y; Qiu M; Wu Q; Tian Y; Zhang Y; Gu N; Li S; Xu L; Yin R
Sci Rep; 2014 Dec; 4():7490. PubMed ID: 25502402
[TBL] [Abstract][Full Text] [Related]
8. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
9. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
10. Specific targeting of nasopharyngeal carcinoma cell line CNE1 by C225-conjugated ultrasmall superparamagnetic iron oxide particles with magnetic resonance imaging.
Liu D; Chen C; Hu G; Mei Q; Qiu H; Long G; Hu G
Acta Biochim Biophys Sin (Shanghai); 2011 Apr; 43(4):301-6. PubMed ID: 21345916
[TBL] [Abstract][Full Text] [Related]
11. The therapeutic effect of PEI-Fe
Zhang H; Li S; Chen F; Ma X; Liu M
Front Oncol; 2023; 13():1080519. PubMed ID: 37091158
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab-conjugated iron oxide nanoparticles for cancer imaging and therapy.
Tseng SH; Chou MY; Chu IM
Int J Nanomedicine; 2015; 10():3663-85. PubMed ID: 26056447
[TBL] [Abstract][Full Text] [Related]
13. Preparation of folic acid-conjugated, doxorubicin-loaded, magnetic bovine serum albumin nanospheres and their antitumor effects in vitro and in vivo.
Yang R; An Y; Miao F; Li M; Liu P; Tang Q
Int J Nanomedicine; 2014; 9():4231-43. PubMed ID: 25228802
[TBL] [Abstract][Full Text] [Related]
14. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
15. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.
Li J; Deng H; Hu M; Fang Y; Vaughn A; Cai X; Xu L; Wan W; Li Z; Chen S; Yang X; Wu S; Xiao J
Oncotarget; 2015 Mar; 6(9):6749-61. PubMed ID: 25730907
[TBL] [Abstract][Full Text] [Related]
17. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
[TBL] [Abstract][Full Text] [Related]
18. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
19. Fe
Lu Q; Dai X; Zhang P; Tan X; Zhong Y; Yao C; Song M; Song G; Zhang Z; Peng G; Guo Z; Ge Y; Zhang K; Li Y
Int J Nanomedicine; 2018; 13():2491-2505. PubMed ID: 29719396
[TBL] [Abstract][Full Text] [Related]
20. Targeting EGFR-overexpressing tumor cells using Cetuximab-immunomicelles loaded with doxorubicin and superparamagnetic iron oxide.
Liao C; Sun Q; Liang B; Shen J; Shuai X
Eur J Radiol; 2011 Dec; 80(3):699-705. PubMed ID: 20810233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
